| Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma MB Overdijk, S Verploegen, M Bögels, M van Egmond, JJL van Bueren, ... MAbs 7 (2), 311-320, 2015 | 546 | 2015 |
| CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma IS Nijhof, T Casneuf, J Van Velzen, B van Kessel, AE Axel, K Syed, ... Blood, The Journal of the American Society of Hematology 128 (7), 959-970, 2016 | 411 | 2016 |
| The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor–mediated cross-linking MB Overdijk, JH Jansen, M Nederend, JJ Lammerts van Bueren, ... The Journal of Immunology 197 (3), 807-813, 2016 | 314 | 2016 |
| Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab IS Nijhof, RWJ Groen, HM Lokhorst, B Van Kessel, AC Bloem, ... Leukemia 29 (10), 2039-2049, 2015 | 310 | 2015 |
| A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization E Drent, M Themeli, R Poels, R de Jong-Korlaar, H Yuan, J de Bruijn, ... Molecular therapy 25 (8), 1946-1958, 2017 | 285 | 2017 |
| Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia A Gutierrez, L Pan, RWJ Groen, F Baleydier, A Kentsis, J Marineau, ... The Journal of clinical investigation 124 (2), 644-655, 2014 | 243 | 2014 |
| Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma E Drent, RWJ Groen, WA Noort, M Themeli, JJL van Bueren, PWHI Parren, ... haematologica 101 (5), 616, 2016 | 195 | 2016 |
| Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib IS Nijhof, RWJ Groen, WA Noort, B van Kessel, R de Jong-Korlaar, ... Clinical cancer research 21 (12), 2802-2810, 2015 | 185 | 2015 |
| Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab J Krejcik, KA Frerichs, IS Nijhof, B van Kessel, JF van Velzen, AC Bloem, ... Clinical cancer research 23 (24), 7498-7511, 2017 | 181 | 2017 |
| Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor–engineered T cells E Drent, R Poels, R Ruiter, NWCJ van de Donk, S Zweegman, H Yuan, ... Clinical Cancer Research 25 (13), 4014-4025, 2019 | 169 | 2019 |
| Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma RWJ Groen, WA Noort, RA Raymakers, HJ Prins, L Aalders, FM Hofhuis, ... Blood, The Journal of the American Society of Hematology 120 (3), e9-e16, 2012 | 162 | 2012 |
| Non-canonical PRC1. 1 targets active genes independent of H3K27me3 and is essential for leukemogenesis V van den Boom, H Maat, M Geugien, AR López, AM Sotoca, J Jaques, ... Cell reports 14 (2), 332-346, 2016 | 156 | 2016 |
| CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia J Naik, M Themeli, R de Jong-Korlaar, RWJ Ruiter, PJ Poddighe, H Yuan, ... Haematologica 104 (3), e100, 2019 | 123 | 2019 |
| Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma EPM Tjin, RWJ Groen, I Vogelzang, PWB Derksen, MD Klok, HP Meijer, ... Blood 107 (2), 760-768, 2006 | 119 | 2006 |
| Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches A Antonelli, WA Noort, J Jaques, B de Boer, R de Jong-Korlaar, ... Blood, The Journal of the American Society of Hematology 128 (25), 2949-2959, 2016 | 101 | 2016 |
| Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance SJ de Haart, NWCJ van de Donk, MC Minnema, JH Huang, ... Clinical cancer research 19 (20), 5591-5601, 2013 | 92 | 2013 |
| Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease A Garcia-Gomez, D Quwaider, M Canavese, EM Ocio, Z Tian, JF Blanco, ... Clinical cancer research 20 (6), 1542-1554, 2014 | 89 | 2014 |
| Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins R Shirasaki, GM Matthews, S Gandolfi, R de Matos Simoes, DL Buckley, ... Cell Reports 34 (1), 2021 | 88 | 2021 |
| Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence A Katsarou, M Sjöstrand, J Naik, J Mansilla-Soto, D Kefala, G Kladis, ... Science translational medicine 13 (623), eabh1962, 2021 | 85 | 2021 |
| Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma RM Reijmers, RWJ Groen, H Rozemuller, A Kuil, A de Haan-Kramer, ... Blood, The Journal of the American Society of Hematology 115 (3), 601-604, 2010 | 77 | 2010 |
Derk ten BergeAssociate Professor, dept of Cell Biology, Erasmus MC University Medical Center Rotterdamبريد إلكتروني تم التحقق منه على erasmusmc.nl
